Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Outline
- Autoimmune diseases
- Example autoimmune diseases
- Clinical features of SLE
- Potential targets for B cell depletion
- Approaches to B cell depletion
- Our approach to B cell depletion
- Clinical features of SLE in mouse models
- Details of CAR T cell immunotherapy
- CAR-treated and control MRL/lpr mice
- IgG serology of CAR-treated MRL/lpr mice
- Flow cytometry of CAR-treated MRL/lpr mice
- Tissue histochemistry
- Testing the persistence of CAR T cells
- B cell transfer experiment
- CD19+ B cells are actively depleted
- Transfer of CD8+ T cells to naïve mice
- A treatment for other autoimmune disorders? (1)
- A treatment for other autoimmune disorders? (2)
- Potential technological advances
- Potential alternative CAR designs
- Conclusions
- Acknowledgements
- Disclosures
Topics Covered
- Mechanisms of autoimmune diseases
- System lupus erythematosus
- Strategies for B cell depletion
- CAR structure and function
- MRL/lpr: a mouse model of lupus
- Testing CD19-targeted CAR in lupus mice
- Potential applications of CAR T cells in autoimmunity
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Radic, M. (2021, June 29). The potential of CAR T cells for the treatment of autoimmune diseases [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/DMTJ3794.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr Marko Radic's financial disclosures includes funding from the Lupus Research Alliance, the National Institute of Health (NIH)) and The Universitee of Tennessee, Health Science Center. Dr Marko Radic is also a consultant for Regeneron, and his research is sponsored by Viela Bio.
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, this is Marko Radic, I am an associate professor at
the University of Tennessee Health Science Center in Memphis,
Tennessee, USA and I will be talking to you about
the potential of CAR T-cells for the treatment of autoimmune diseases.
I think this is something that will appeal to
a broad range of interests, in both basic and applied medicine.
0:29
The outline of my talk is to define autoimmune diseases and touch upon their mechanisms,
then to describe to you a disease called systemic lupus erythematosus (SLE for short).
I will talk about strategies for B-cell depletion,
then I will introduce you to the topic of
chimeric antigen receptors (or CARs) and their structure and function.
I will talk to you about the MRL/lpr mouse model for lupus,
then I will describe the experiments that we did to
test CD19-targeted CARs in lupus mice.
I will present data for that from the Radic laboratory.
I will also talk to you about potential applications of the CD19 CAR in
other autoimmune diseases, and I will summarize
future perspectives and devise ways forward.
1:31
Autoimmune diseases affect quite
a large number of individuals in the overall population,
it's estimated that at least 1 in 13 individuals
(more than seven percent of people at large) suffer from an autoimmune disorder.
Autoimmune diseases are defined as a disorder that
is usually chronic, and in which any component of the immune system
(that normally protects us from infection) mistakenly attacks the host body.
There are diverse diseases and each has a unique mechanism,
those mechanisms may include:
B-cells that produce autoantibodies;
T-cells, which can attack or stimulate other cells in the body,
but mostly act through a cytotoxic mechanism;
to various degrees the innate immune system is also involved,
which can cause inflammation or inappropriate coagulation.
Hide